New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines 25/02/2021 - 14:30 '); '); MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine sub-study show protective influenza antibody levels at four weeks post-vaccination in MS patients taking MAVENCLAD In both studies, protective antibody levels were maintained or increased independent of lymphocyte counts DARMSTADT, Germany, Feb. 25, 2021 /PRNewswire/ -- Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD® (cladribine tablets) in patients with relapsing multiple sclerosis (RMS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, being held virtually 25-27 February 2021. The data indicate that RMS patients receiving MAVENCLAD are able to mount a response to seasonal influenza and varicella zoster vaccination.